Immorta Bio Announces a Significant Breakthrough in Treatment of Liver Failure

Overview

Immorta Bio Inc, a biotechnology company developing efficient and practical personalized stem cell platforms aimed at treating diseases of aging, has announced patent filing on successful treatment of the carbon tetrachloride model of liver failure using its PMSC-11 stem cell therapy. Data disclosed in its filed patent demonstrates PMSC-11 potently suppresses liver damage as detected by preserving albumin production and blocking catastrophic rises in liver enzymes which are typical in liver failure.  Importantly, the administration of the PMSC-11 stem cell product induced a potent increase in a totally unexpected cytokine whose expression in some publications has been correlated with accelerated recovery from hepatic failure.

Words from Immorta Bio

• "age than the patient,"" said Dr. Thomas Ichim, president and chief scientific officer of Immorta Bio. 
• "The PMSC-11 cells, utilized in the experiments reported today, demonstrated safety as well as therapeutic efficacy, supporting continued development of this ""First in Class"" Stem Cell Therapy for liver failure."

Liver Failure

"Liver Failure is the fifth leading cause of death world-wide with no therapeutic options besides transplantation. We are conducting pre-clinical experiments in animals using human cells to demonstrate safety and efficacy of these cells before applying to the FDA to begin clinical trials,"" said Dr. Vlad Bykoriz, chief medical officer of Immorta Bio.

Stem Cells

• Stem cells have previously been demonstrated to possess some therapeutic effects on liver failure, however allogeneic stem cells, that have been mostly used so far, are eventually rejected by the patient. 
• And autologous adult stem cells are limited in numbers, and often dysfunctional because of preexisting conditions. 
• The PMSC product overcomes some of the shortcomings of existing stem cell therapeutics. 
• These cells are patient specific, ""biologically younger"", and can be created in unlimited numbers because they are derived from the embryonic-like PRC.

Words from Chairman: Immorta Bio

• "Our vision of significant life extension is based on revivifying aged or damaged organs," said Dr. Boris Reznik, CEO and chairman of the company. 
• "We generate "Amenable Stem Cells" (ASC) from a tablespoon of patient's blood and utilize our proprietary technology to transform these ASC into "Personalized Regenerative Cells" (PRC).  The PRC are very similar to the immortal embryonic stem cells and are generated by "reverse differentiation" of the ASC from the patient's blood.  
• These PRC should allow for creation and introduction of cells for any tissue or organ whose regeneration is desired. Today's announcement provides a glimpse into the potential power of our Stem Cell Revivify path to organ and eventually whole-body rejuvenation."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!